Peptineo Announces Appointment of David M. Wyatt to Advisory Board
Albuquerque, NM, March 27, 2014 --(PR.com
)-- Peptineo is pleased to announce the appointment of David M. Wyatt to their advisory board.
David has had over 25 years of technical and business experience in the development of controlled release pharmaceutical products. He has held senior management positions in sales and business development, global strategic business management with P&L responsibility, as well as direct technical formulation experience and development in the area of controlled release. He has considerable experience and knowledge in the use of GMP excipients for targeted release and early stage product development. This includes polymers, high valued phospholipids, nanoparticles, and electronic technologies for oral drug delivery. He has worked in developments associated with liposomal delivery, cationic delivery of RNAi, and polymeric delivery, for both the delivery of large and small molecules including peptides and proteins. He has also worked in the area of GMP custom manufacturing for peptides and amino acid derivatives, as well as small molecules and API’s. His analytical chemistry experience covers chromatographic and spectroscopic techniques. He holds a MS degree in analytical chemistry from the University of Georgia at Athens and a BS degree in Chemistry from the University of North Carolina at Chapel Hill.
He has also had considerable experience in techniques associated with marketing communications and promotional developments. He has authored over a dozen corporate brochures in pharmaceutical excipients and oral release, as well as published articles and presentations in both pharmaceuticals and analytical chemistry. He has led efforts in developments of websites and customer databases for use in customer communications. As a member of several major trade associations and conferences he has participated in the AAPS, CRS, TIDES, and Drug Delivery Partnerships. David will advise Peptineo on its commercial efforts in all aspects of business with special emphasis on the acetylated dextran line of controlled release polymers.